Skip to main content
Assets
Abbott Laboratories logo
ABT.NYSE
Abbott Laboratories
Health Care · Health Care Equipment

Global healthcare company developing medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Abbott Laboratories.

Historical AI Opinions

Abbott Laboratories (ABT.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ResearcherAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+85.2%

Includes 1.77% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.70.68110.89151.11191.33231.55Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$143+10.9%Not Generated this time
$151+17.7%Not Generated this time
$161+25.0%Not Generated this time
$169+31.3%Not Generated this time
$178+38.6%Not Generated this time
$187+45.2%Not Generated this time
$194+51.0%Not Generated this time
$203+57.7%Not Generated this time
$210+63.5%Not Generated this time
$218+69.7%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

Abbott is projected to deliver consistent, defensive growth underpinned by its diversified business model. The successful European rollout of Volt PFA (CE Mark 2025) serves as a prelude to a robust US launch in 2026, offsetting maturity in legacy diagnostics. The FreeStyle Libre franchise continues to grow double-digits as it expands into the 'biowearable' consumer market, proving complementary to weight-loss drugs. While NEC litigation remains a headline risk, the mixed verdict history suggests a manageable eventual resolution rather than a catastrophic financial event. Financial performance is expected to show high-single-digit revenue growth and double-digit EPS expansion, supporting a valuation re-rating to historical averages (~24-25x P/E) as the 'post-COVID' normalization fully resolves.

2. Scenarios & Signals

2.1. Bull Case

In this scenario, Abbott enters a 'MedTech Renaissance' driven by the successful US launch of the Volt Pulsed Field Ablation (PFA) system in 2026, which rapidly captures market share in the electrophysiology space. The FreeStyle Libre platform achieves ubiquitous adoption among Type 2 non-insulin users and pre-diabetics, positioning it as a premier wellness tool alongside GLP-1 therapies rather than a victim of them. Litigation risks related to NEC formula claims dissipate significantly following a string of courtroom victories similar to the October 2024 ruling, effectively capping liability exposure. Macroeconomic tailwinds, including a weaker dollar and lower interest rates, boost international earnings (EPD) and valuation multiples, driving the P/E ratio toward 28-30x as EPS growth accelerates to the mid-teens.

2.2. Bear Case

The bear case assumes a resurgence of legal headwinds where the July 2024 adverse verdict in the NEC formula litigation becomes a trend, forcing Abbott into a multibillion-dollar structured settlement that weighs on free cash flow and dividends for years. Concurrently, long-term data on GLP-1 agonists begins to show a tangible reduction in cardiovascular events and diabetes progression, leading to slowing volume growth for structural heart devices and CGMs. Pricing pressure in China (Volume-Based Procurement) intensifies across diagnostics and pharmaceuticals, eroding margins. Market sentiment sours, compressing the P/E multiple to ~18x as investors view the company as a low-growth legacy conglomerate rather than a high-growth innovator.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 2,349Thinking Tokens: 949Response Tokens: 7,495Total Tokens: 10,793
Researcher modeSearch enabled · not used

This run was configured as Researcher, but no external search activity was recorded. The model proceeded from the supplied context as sufficient, effectively following a Thinker-style workflow.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced System Instruction Driven Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.